Top

Journal of Cancer Research and Clinical Oncology

Published in:

28-02-2023 | Review

Clinical and economic impact of clinical oncology pharmacy in cancer patients receiving injectable anticancer treatments: a systematic review

Authors: Claire Lattard, Amandine Baudouin, Virginie Larbre, Chloé Herledan, Ariane Cerutti, Marie-Anne Cerfon, Reine Kimbidima, Anne-Gaelle Caffin, Nicolas Vantard, Vérane Schwiertz, Florence Ranchon, Catherine Rioufol

Published in: Journal of Cancer Research and Clinical Oncology | Issue 10/2023

Abstract

Purpose

Clinical pharmacy can reduce drug-related iatrogenesis by improving the management of adverse effects of drugs, limiting drug–drug interactions, and improving patient adherence. Given the vulnerability of cancer patients and the toxicity of injectable anticancer drugs, clinical pharmacy service (CPS) could provide a significant clinical benefit in cancer care. This review aims to synthesize existing evidence on clinical pharmacy’s impact on patients treated with intravenous anticancer drugs.

Methods

A comprehensive search was performed in the PubMed/Medline database from January 2000 to December 2021, associating the keywords: clinical pharmacy, pharmaceutical care, pharmacist, oncology, and chemotherapy. To be eligible for inclusion, studies have to report clinical pharmaceutical services for patients treated with intravenous chemotherapy with a clinical and/or economic impact.

Results

Forty-one studies met the selection criteria. Various CPS were reported: medication reconciliation, medication review, and pharmaceutical interview with patient. There was a lack of randomized study (n = 3; 7.3%). In one randomized controlled trial, pharmaceutical intervention significantly improved quality of life of patients receiving pharmaceutical care during injectable anticancer drugs courses. Economical results appear to show positive impact of clinical pharmacy with cost savings reported from 3112.87$ to 249 844€. Although most studies were non-comparative, they highlighted that clinical pharmacy tend to limit chemotherapy side effects and drug-related problems, improve quality of life and satisfaction of patients and healthcare professional, and a positive economic impact.

Conclusion

Clinical pharmacy can reduce adverse drug events in cancer patients. More robust and economic evaluations are still required to support its development in everyday practice.

Ahmed A, Saqlain M, Tanveer M, Blebil AQ, Dujaili JA, Hasan SS (2021) The impact of clinical pharmacist services on patient health outcomes in Pakistan: a systematic review. BMC Health Serv Res 21:859PubMedPubMedCentral

Ali K, Al-Quteimat O, Naseem R, Malhi SM, Wajdi M, Jahan N et al (2021) Incorporating a clinical oncology pharmacist into an ambulatory care pharmacy in pediatric hematology-oncology and transplant clinic: Assessment and significance. J Oncol Pharm Pract 27(4):815–820PubMed

Allison J, Fisher J, Souter C, Bennie M (2019) What patient assessment skills are required by pharmacists prescribing systemic anti-cancer therapy? A consensus study. J Oncol Pharm Pract 25(8):1933–1944PubMed

Al-Taie A, Izzettin FV, Sancar M et al (2020) Impact of clinical pharmacy recommendations and patient counselling program among patients with diabetes and cancer in outpatient oncology setting. Eur J Cancer Care 29:e13261

American College of Clinical Pharmacy (2008) The definition of clinical pharmacy. Pharmacotherapy 28(6):816–817

Ashjian E, Salamin LB, Eschenburg K, Kraft S, Mackler E (2015) Evaluation of outpatient medication reconciliation involving student pharmacists at a comprehensive cancer center. J Am Pharm Assoc 55(5):540–545

Barral M, Martin J, Carre E, Janoly-Dumenil A, Ranchon F, Parat S, Rioufol C et al (2021) 5P Study Group. How a patient personalised clinical pharmacy programme can secure therapeutic care in an orthogeriatric care pathway (5P Project). Clin Interv Aging 16:1857–1867PubMedPubMedCentral

Basch E, Deal AM, Dueck AC, Scher HI, Kris MG, Hudis C, Schrag D (2017) Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. JAMA 318:197–198PubMedPubMedCentral

Bates JS, Auten J, Sketch MR, Patel T, Clark SM, Morgan KP et al (2019) Patient engagement in first cycle comprehensive chemotherapy consultation pharmacist services and impact on patient activation. J Oncol Pharm Pract 25(4):896–902PubMed

Baudouin A, Herledan C, Poletto N, Guillemin MD, Maison O, Garreau R et al (2021) Economic impact of clinical pharmaceutical activities in hospital wards: a systematic review. Res Social Adm Pharm 17(3):497–505PubMed

Ben-Arye E, Samuels N, Goldstein LH, Mutafoglu K, Omran S, Schiff E et al (2016) Potential risks associated with traditional herbal medicine use in cancer care: a study of Middle Eastern oncology health care professionals. Cancer 122(4):598–610PubMed

Boşnak AS, Birand N, Diker Ö, Abdi A, Başgut B (2019) The role of the pharmacist in the multidisciplinary approach to the prevention and resolution of drug-related problems in cancer chemotherapy. J Oncol Pharm Pract 25(6):1312–1320PubMed

Caracuel F, Baños Ú, Herrera MD, Ramírez G, Muñoz N (2014) Influence of pharmaceutical care on the delayed emesis associated with chemotherapy. Int J Clin Pharm 36(2):287–290PubMed

Chan A, Shih V, Chiang J, Chew L, Tay K, Quek R et al (2013) Clinical pharmacy services and research for lymphoma patients at a cancer center. J Oncol Pharm Pract 19(1):24–30PubMed

Chew C, Chiang J, Yeoh TT (2015) Impact of outpatient interventions made at an ambulatory cancer centre oncology pharmacy in Singapore. J Oncol Pharm Pract 21(2):93–101PubMed

Collomb B, Dubromel A, Caffin AG, Herledan C, Larbre V, Baudouin A et al (2022) Assessment of patient reported outcomes (PROs) in outpatients taking oral anticancer drugs included in the real-life oncoral program. Cancers (basel) 14(3):660PubMed

Crespo A, Tyszka M (2017) Evaluating the patient-perceived impact of clinical pharmacy services and proactive follow-up care in an ambulatory chemotherapy unit. J Oncol Pharm Pract 23(4):243–248PubMed

da Silva BA, Krishnamurthy M (2016) The alarming reality of medication error: a patient case and review of Pennsylvania and National data. J Community Hosp Intern Med Perspect 6(4):31758PubMed

Damery S, Gratus C, Grieve R, Warmington S, Jones J, Routledge P, Greenfield S, Dowswell G, Sherriff J, Wilson S (2011) The use of herbal medicines by people with cancer: A cross-sectional survey. Br J Cancer 104:927–933PubMedPubMedCentral

Daupin J, Perrin G, Lhermitte-Pastor C, Loustalot MC, Pernot S, Savoldelli V et al (2019) Pharmaceutical interventions to improve safety of chemotherapy-treated cancer patients: a cross-sectional study. J Oncol Pharm Pract 25(5):1195–1203PubMed

de Grégori J, Pistre P, Boutet M, Porcher L, Devaux M, Pernot C et al (2020) Clinical and economic impact of pharmacist interventions in an ambulatory hematology-oncology department. J Oncol Pharm Pract 26(5):1172–1179PubMed

Delpeuch A, Leveque D, Gourieux B, Herbrecht R (2015) Impact of clinical pharmacy services in a hematology/oncology inpatient setting. Anticancer Res 35(1):457–460PubMed

Döhler N, Krolop L, Ringsdorf S, Meier K, Ko YD, Kuhn W et al (2011) Task allocation in cancer medication management - integrating the pharmacist. Patient Educ Couns 83(3):367–374PubMed

Dreischulte T, van den Bemt B, Steurbaut S (2022) European Society of Clinical Pharmacy definition of the term clinical pharmacy and its relationship to pharmaceutical care: a position paper. Int J Clin Pharm 44(4):837–842PubMedPubMedCentral

Edwards SJ, Abbott R, Edwards J, LeBlanc M, Dranitsaris G, Donnan J et al (2014) Outcomes assessment of a pharmacist-directed seamless care program in an ambulatory oncology clinic. J Pharm Pract 27(1):46–52PubMed

Edwards Z, Ziegler L, Craigs C, Blenkinsopp A, Bennett MI (2019) Pharmacist educational interventions for cancer pain management: a systematic review and meta-analysis. Int J Pharm Pract 27(4):336–345PubMed

Engdal S, Steinsbekk A, Klepp O, Nilsen OG (2008) Herbal use among cancer patients during palliative or curative chemotherapy treatment in Norway. Support Care Cancer 16(7):763–769PubMed

Farias TF, Aguiar KD, Rotta I, Belletti KM, Carlotto J (2016) Implementing a clinical pharmacy service in hematology. Einstein (sao Paulo) 14(3):384–390PubMed

Gandhi TK, Bartel SB, Shulman LN, Verrier D, Burdick E, Cleary A et al (2005) Medication safety in the ambulatory chemotherapy setting. Cancer 104(11):2477–2483PubMed

Gerber A, Da Silva LA, Szüts N, Simon M, Ribordy-Baudat V, Ebneter A et al (2020) Describing adverse events in Swiss hospitalized oncology patients using the Global Trigger Tool. Health Sci Rep 3(2):e160PubMedPubMedCentral

Granados J, Salazar-Ospina A, Botero-Aguirre JP, Valencia-Quintero AF, Ortiz N, Amariles P (2020) Effect and associated factors of a clinical pharmacy model in the incidence of medication errors (EACPharModel) in the Hospital Pablo Tobón Uribe: study protocol for a stepped wedge randomized controlled trial (NCT03338725). Trials 21(1):26PubMedPubMedCentral

Griese-Mammen N, Hersberger KE, Messerli M, Leikola S, Horvat N, van Mil JWF et al (2018) PCNE definition of medication review: reaching agreement. Int J Clin Pharm 40(5):1199–1208PubMed

Guo Q, Guo H, Song J et al (2020) The role of clinical pharmacist trainees in medication reconciliation process at hospital admission. Int J Clin Pharm 42(2):796–804PubMed

Gurwitz JH, Kapoor A, Garber L et al (2021) Effect of a multifaceted clinical pharmacist intervention on medication safety after hospitalization in persons prescribed high-risk medications: a randomized clinical trial. JAMA Intern Med 181(5):610–618PubMedPubMedCentral

Hamel C, Tortolano L, Bermudez E, Desmaris R, Klein S, Slimano F et al (2018) Computerized pediatric oncology prescriptions review by pharmacist: A descriptive analysis and associated risk factors. Pediatr Blood Cancer 65(4):e26897

Han JM, Ah YM, Suh SY, Jung SH, Hahn HJ, Im SA et al (2016) Clinical and economic impact of pharmacists’ intervention in a large volume chemotherapy preparation unit. Int J Clin Pharm 38(5):1124–1132PubMed

Hatoum HT, Hutchinson RA, Witte KW et al (1988) Evaluation of the contribution of clinical pharmacists: inpatient care and cost reduction. Drug Intell Clin Pharm 22:252–259PubMed

Haukland EC, von Plessen C, Nieder C, Vonen B (2017) Adverse events in hospitalized cancer patients: a comparison to a general hospital population. Acta Oncol 56(9):1218–1223PubMed

Herledan C, Baudouin A, Larbre V, Gahbiche A, Dufay E, Alquier I et al (2020) Clinical and economic impact of medication reconciliation in cancer patients: a systematic review. Support Care Cancer 28(8):3557–3569PubMed

Hibbard JH, Stockard J, Mahoney ER, Tusler M (2004) Development of the Patient Activation Measure (PAM): conceptualizing and measuring activation in patients and consumers. Health Serv Res 39(4 Pt 1):1005–1026PubMedPubMedCentral

Hirose C, Fujii H, Iihara H, Ishihara M, Nawa-Nishigaki M, Kato-Hayashi H et al (2020) Real-world data of the association between quality of life using the EuroQol 5 Dimension 5 Level utility value and adverse events for outpatient cancer chemotherapy. Support Care Cancer 28(12):5943–5952PubMedPubMedCentral

Holle LM, Harris CS, Chan A, Fahrenbruch RJ, Labdi BA, Mohs JE et al (2017) Pharmacists’ roles in oncology pharmacy services: Results of a global survey. J Oncol Pharm Pract 23(3):185–194PubMed

Homan MJ, Reid JH, Nachar VR, Benitez LL, Brown AM, Kraft S et al (2021) Implementation and outcomes of a pharmacist-led collaborative drug therapy management program for oncology symptom management. Support Care Cancer 29(11):6505–6510PubMed

Horneber M, Bueschel G, Dennert G et al (2012) How many cancer patients use complementary and alternative medicine: a systematic review and meta-analysis. Integr Cancer Ther 11:187–203PubMed

Imamura M, Ogawa D, Takatori T, Yamaguchi M, Takata T, Hada T et al (2017) A retrospective study of the effects of oncology pharmacist participation in treatment on therapeutic outcomes and medical costs. Biol Pharm Bull 40(11):1956–1962PubMed

Ismail M, Khan S, Khan F, Noor S, Sajid H, Yar S et al (2020) Prevalence and significance of potential drug-drug interactions among cancer patients receiving chemotherapy. BMC Cancer 20(1):335PubMedPubMedCentral

Jacobson JO, Polovich M, McNiff KK, Lefebvre KB, Cummings C, Galioto M et al (2009) American Society Of Clinical Oncology/Oncology Nursing Society chemotherapy administration safety standards. J Clin Oncol 27(32):5469–5475PubMed

Jarfaut A, Nivoix Y, Vigouroux D, Kehrli P, Gaudias J, Kempf JF et al (2014) Clinical pharmacy and surgery: Review. Ann Pharm Fr 72(3):152–163PubMed

Kabel AM, Bakr MM, Alshanbari AM, Alwagdani SM, Altalhi HA, Alzaidi SH et al (2020) Perceptions and attitudes towards clinical pharmacy services and their impact on the management of cancer in Taif, Saudi Arabia. Asian Pac J Cancer Prev 21(2):531–538PubMedPubMedCentral

Kaya M, Nakamura K, Nagamine M, Suyama Y, Nakajo M, Uchida R et al (2021) A retrospective study comparing interventions by oncology and non-oncology pharmacists in outpatient chemotherapy. Cancer Rep 4(4):e1371

Knez L, Laaksonen R, Duggan C (2010) Evaluation of clinical interventions made by pharmacists in chemotherapy preparation. Radiol Oncol 44(4):249–256PubMedPubMedCentral

Korayem GB, Badreldin HA, Eljaaly K, Aldemerdash A, Al-Suhaibani LK, Joharji H et al (2021) Clinical pharmacy definition, required education, training and practice in Saudi Arabia: A position statement by the Saudi society of clinical pharmacy. Saudi Pharm J 29(11):1343–1347PubMedPubMedCentral

Kucuk E, Bayraktar-Ekincioglu A, Erman M, Kilickap S (2020) Drug-related problems with targeted/immunotherapies at an oncology outpatient clinic. J Oncol Pharm Pract 26(3):595–602PubMed

Lau KM, Saunders IM, Sacco AG, Barnachea LC (2020) Evaluation of pharmacist interventions in a head and neck medical oncology clinic. J Oncol Pharm Pract 26(6):1390–1396PubMed

Laurent V, Saillard J, Thierry M, Lepelletier A, Fronteau C, Huon JF (2021) Anticancer agents and herbal medicine: Interactions that are often unrecognized. J Oncol Pharm Pract 27(2):322–328PubMed

Le Guen R, Madelaine I, Tournamille JF, Bellanger A, Astier A, Braguer D et al (2015) Study impacto: Descriptive analyzis of pharmacist’s clinical practice in onco-hematology. Ann Pharm Fr 73(3):223–228PubMed

Le S, Chang B, Pham A, Chan A (2021) Impact of pharmacist-managed immune checkpoint inhibitor toxicities. J Oncol Pharm Pract 27(3):596–600PubMed

Lee RT, Kwon N, Wu J, To C, To S, Szmulewitz R et al (2021) Prevalence of potential interactions of medications, including herbs and supplements, before, during, and after chemotherapy in patients with breast and prostate cancer. Cancer 127(11):1827–1835PubMed

Liekweg A, Westfeld M, Braun M, Zivanovic O, Schink T, Kuhn W et al (2012) Pharmaceutical care for patients with breast and ovarian cancer. Support Care Cancer 20(11):2669–2677PubMedPubMedCentral

Lihara H, Ishihara M, Matsuura K, Kurahashi S, Takahashi T, Kawaguchi Y et al (2012) Pharmacists contribute to the improved efficiency of medical practices in the outpatient cancer chemotherapy clinic. J Eval Clin Pract 18(4):753–760

Lipitz-Snyderman A, Pfister D, Classen D, Atoria CL, Killen A, Epstein AS et al (2017) Preventable and mitigable adverse events in cancer care: Measuring risk and harm across the continuum. Cancer 123(23):4728–4736PubMed

Lopez-Martin C, Garrido Siles M, Alcaide-Garcia J, Faus FV (2014) Role of clinical pharmacists to prevent drug interactions in cancer outpatients: a single-centre experience. Int J Clin Pharm 36(6):1251–1259PubMed

Maleki S, Alexander M, Fua T, Liu C, Rischin D, Lingaratnam S (2019) A systematic review of the impact of outpatient clinical pharmacy services on medication-related outcomes in patients receiving anticancer therapies. J Oncol Pharm Pract 25(1):130–139PubMed

Martínez-Bautista MJ, Mangues-Bafalluy I, Cajaraville-Ordoñana G, Carreras-Soler MJ, Clopés-Estela A, Moreno-Martínez E (2019) Survey of oncohematological pharmaceutical care situation in Spain. Farma Hosp 43(6):194–201

McKee M, Frei BL, Garcia A, Fike D, Soefje SA (2011) Impact of clinical pharmacy services on patients in an outpatient chemotherapy academic clinic. J Oncol Pharm Pract 17(4):387–394PubMed

Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7):e1000097PubMedPubMedCentral

Morimoto Y, Takei H, Tachibana K, Nakazato Y, Tanaka R, Nagashima Y et al (2018) Role of pharmacists in completion of adjuvant cisplatin-vinorelbine chemotherapy in japanese patients with non-small cell lung cancer. Yakugaku Zasshi 138(3):437–442PubMed

Moukafih B, Abahssain H, Mrabti H, Errihani H, Rahali Y, Taoufik J et al (2021) Impact of clinical pharmacy services in a hematology/oncology ward in Morocco. J Oncol Pharm Pract 27(2):305–311PubMed

Muñoz-Pichuante D, Villa-Zapata L (2020) Benefit of incorporating clinical pharmacists in an adult intensive care unit: a cost-saving study. J Clin Pharm Ther 45:1127–1133PubMed

Nerich V, Borg C, Villanueva C, Thiery-Vuillemin A, Helias P, Rohrlich PS et al (2013) Economic impact of prescribing error prevention with computerized physician order entry of injectable antineoplastic drugs. J Oncol Pharm Pract 19(1):8–17PubMed

Oliveira CS, Silva MP, Miranda ÍK, Calumby RT, de Araújo-Calumby RF (2021) Impact of clinical pharmacy in oncology and hematology centers: a systematic review. J Oncol Pharm Pract 27(3):679–692PubMed

Omar NE, Elazzazy S, Abdallah O, Nashwan AJ, Eltorki Y, Afifi HM et al (2020) Perceptions and expectations of health care providers towards clinical pharmacy services at a tertiary cancer centre in Qatar. J Oncol Pharm Pract 26(5):1086–1096PubMed

Opsomer MA, Anota A, Noblot-Rossignol M, Bonnetain F, Pernot C, Chretien ML et al (2016) Impact of pharmaceutical intervention on quality of life and coping strategies in patients with haematological malignancies. Ann Pharm Fr 74(6):439–447PubMed

Overhage JM, Lukes A (1999) Practical, reliable, comprehensive method for characterizing pharmacists’ clinical activities. Am J Health Syst Pharm 56(23):2444–2450PubMed

Penm J, Vaillancourt R, Pouliot A (2019) Defining and identifying concepts of medication reconciliation: an international pharmacy perspective. Res Social Adm Pharm 15(6):632–640PubMed

Ramos-Esquivel A, Víquez-Jaikel Á, Fernández C (2017) Potential drug-drug and herb-drug interactions in patients with cancer: a prospective study of medication surveillance. J Oncol Pract 13(7):e613–e622PubMed

Ranchon F, Salles G, Späth HM, Schwiertz V, Vantard N, Parat S et al (2011) Chemotherapeutic errors in hospitalised cancer patients: attributable damage and extra costs. BMC Cancer 11:478PubMedPubMedCentral

Ranchon F, Moch C, You B, Salles G, Schwiertz V, Vantard N et al (2012) Predictors of prescription errors involving anticancer chemotherapy agents. Eur J Cancer 48(8):1192–1199PubMed

Renna CE, Dow EN, Bergsbaken JJ, Leal TA (2019) Expansion of pharmacist clinical services to optimize the management of immune checkpoint inhibitor toxicities. J Oncol Pharm Pract 25(4):954–960PubMed

Riechelmann RP, Tannock IF, Wang L, Saad ED, Taback NA, Krzyzanowska MK (2007) Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst 99(8):592–600PubMed

Ruder AD, Smith DL, Madsen MT, Kass FH 3rd (2011) Is there a benefit to having a clinical oncology pharmacist on staff at a community oncology clinic? J Oncol Pharm Pract 17(4):425–432PubMed

Sam S, Guérin A, Rieutord A, Belaiche S, Bussières JF (2018) Roles and impacts of the transplant pharmacist: a systematic review. Can J Hosp Pharm 71(5):324–337PubMedPubMedCentral

Schindel TJ, Given LM (2013) The pharmacist as prescriber: a discourse analysis of newspaper media in Canada. Res Social Adm Pharm 9(4):384–395PubMed

Segal EM, Bates J, Fleszar SL, Holle LM, Kennerly-Shah J, Rockey M et al (2019) Demonstrating the value of the oncology pharmacist within the healthcare team. J Oncol Pharm Pract 25(8):1945–1967PubMed

Shah S, Dowell J, Greene S (2006) Evaluation of clinical pharmacy services in a hematology/oncology outpatient setting. Ann Pharmacother 40(9):1527–1533PubMed

Shrestha S, Shakya D, Palaian S (2020) Clinical pharmacy education and practice in nepal: a glimpse into present challenges and potential solutions. Adv Med Educ Pract 11:541–548PubMedPubMedCentral

Société Française de Pharmacie Clinique. Lexique de Pharmacie Clinique. [Online]. 2018 [consulted 20/12/2021]. Available on: https://sfpc.eu/wp-content/uploads/2019/11/1-s.0.S2211104218302005-mmc1.pdf

Son H, Kim J, Kim C, Ju J, Lee Y, Rhie SJ (2018) Pharmacist-led interdisciplinary medication reconciliation using comprehensive medication review in gynaecological oncology patients: a prospective study. Eur J Hosp Pharm 25(1):21–25PubMed

Stämpfli D, Baumgartner P, Boeni F et al (2019) Translation and validation of a tool to assess the impact of clinical pharmacists’ interventions. Int J Clin Pharm 41:56–64PubMed

Suzuki H, Suzuki S, Kamata H, Sugama Y, Demachi K, Ikegawa K et al (2019) Impact of pharmacy collaborating services in an outpatient clinic on improving adverse drug reactions in outpatient cancer chemotherapy. J Oncol Pharm Pract 25(7):1558–1563PubMed

Tariq RA, Vashisht R, Sinha A, Scherbak Y (2021) StatPearls [Internet] Treasure Island, FL: StatPearls Publishing. Medication dispensing errors and prevention

Tefera GM, Zeleke AZ, Jima YM, Kebede TM (2020) Drug therapy-related problems and the role of clinical pharmacist in surgery Ward: prospective observational and interventional study. Drug Healthc Patient Saf 12:71–83PubMedPubMedCentral

Tezcan S, İzzettin FV, Sancar M, Turhal NS, Yumuk PF (2018) Role of clinical oncology pharmacist in determination of pharmaceutical care needs in patients with colorectal cancer. Eur J Hosp Pharm 25(e1):e17–e20PubMed

Theuser AK, Hack CC, Fasching PA, Antoniadis S, Grasruck K, Wasner S et al (2021) Patterns and trends of herbal medicine use among patients with gynecologic cancer. Geburtshilfe Frauenheilkd 81(6):699–707PubMedPubMedCentral

Tissot M, Valnet-Rabier M, Stalder T, Limat S, Davani S, Nerich V (2021) Epidemiology and economic burden of “serious” adverse drug reactions: Real-world evidence research based on pharmacovigilance data. Therapies 77:291

Van der Linden L, Hias J, Walgraeve K, Flamaing J, Tournoy J, Spriet I (2020) Clinical pharmacy services in older inpatients: an evidence-based review. Drugs Aging 37(3):161–174PubMed

van Leeuwen RW, Swart EL, Boven E et al (2011) Potential drug interactions in cancer therapy: A prevalence study using an advanced screening method. Ann Oncol 22:2334–2341PubMed

van Leeuwen RWF, Jansman FGA, van den Bemt P, de Man F, Piran F, Vincenten I et al (2015) Drug-drug interactions in patients treated for cancer: a prospective study on clinical interventions. Ann Oncol 26(5):992–997PubMed

van Mil JWF, Westerlund LOT, Hersberger KE, Schaefer MA (2004) Drug-related problem classification systems. Ann Pharmacother 38:859–867PubMed

Vantard N, Ranchon F, Schwiertz V, Gourc C, Gauthier N, Guedat MG et al (2015) EPICC study: evaluation of pharmaceutical intervention in cancer care. J Clin Pharm Ther 40(2):196–203PubMed

Vega TG, Sierra-Sánchez JF, Martínez-Bautista MJ, García-Martín F, Suárez-Carrascosa F, Baena-Cañada JM (2016) Medication reconciliation in oncological patients: a randomized clinical trial. J Manag Care Spec Pharm 22(6):734–740PubMed

Vucur C, Wirtz DA, Weinhold L, Zipfel M, Schmid M, Schmidt-Wolf IG et al (2021) Drug-related problems in head and neck cancer patients identified by repeated medication reviews on consecutive therapy cycles. J Oncol Pharm Pract 27(6):1439–1446PubMed

Walsh KE, Dodd KS, Seetharaman K, Roblin DW, Herrinton LJ, Von Worley A et al (2009) Medication errors among adults and children with cancer in the outpatient setting. J Clin Oncol 27(6):891–896PubMed

Wang Y, Wu H, Xu F (2015) Impact of clinical pharmacy services on KAP and QOL in cancer patients: a single-center experience. Biomed Res Int 2015:502431PubMedPubMedCentral

Weingart SN, Zhang L, Sweeney M, Hassett M (2018) Chemotherapy medication errors. Lancet Oncol 19(4):e191–e199PubMed

Xie C, Mu X, Hu Z, Wang W, Huang W, Huang G et al (2020) Impact of pharmaceutical care in the orthopaedic department. J Clin Pharm Ther 45(3):401–407PubMed

Xu P, Hu YY, Yuan HY, Xiang DX, Zhou YG, Cave AJ, Banh HL (2019) the impact of a training program on clinical pharmacists on pharmacy clinical services in a tertiary hospital in Hunan China. J Multidiscip Healthc 12:975–980PubMedPubMedCentral

Zecchini C, Vo TH, Chanoine S, Lepelley M, Laramas M, Lemoigne A, Allenet B, Federspiel I, Bedouch P (2020) BMC Health Serv Res 20(1):113PubMedPubMedCentral

Zhou M, Desborough J, Parkinson A, Douglas K, McDonald D, Boom K (2019) Barriers to pharmacist prescribing: a scoping review comparing the UK, New Zealand, Canadian and Australian experiences. Int J Pharm Pract 27(6):479–489PubMed

Title: Clinical and economic impact of clinical oncology pharmacy in cancer patients receiving injectable anticancer treatments: a systematic review
Authors: Claire Lattard
Amandine Baudouin
Virginie Larbre
Chloé Herledan
Ariane Cerutti
Marie-Anne Cerfon
Reine Kimbidima
Anne-Gaelle Caffin
Nicolas Vantard
Vérane Schwiertz
Florence Ranchon
Catherine Rioufol
Publication date: 28-02-2023
Publisher: Springer Berlin Heidelberg
Published in: Journal of Cancer Research and Clinical Oncology / Issue 10/2023
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-023-04630-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 10/2023

FTO-mediated m6A modification promotes malignant transformation of gastric mucosal epithelial cells in chronic Cag A+ Helicobacter pylori infection

Neuroendocrine differentiation predicts the therapeutic efficacy of abiraterone and docetaxel as first-line therapy in metastatic castration-resistant prostate cancer

Long non-coding RNAs enable precise diagnosis and prediction of early relapse after nephrectomy in patients with renal cell carcinoma

Survival outcomes of patients newly diagnosed with diffuse large B-cell lymphoma: real-world evidence from a German claims database

Immune checkpoint inhibitor-induced hypophysitis: clinical and biochemical features

Oncolytic adenoviruses and the treatment of pancreatic cancer: a review of clinical trials

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials